Fakebatch of botulinum toxin identified by Anvisa.
The Brazilian Health Regulatory Agency (Anvisa) has ordered the immediate withdrawal of a counterfeit batch of Dysport, a botulinum toxin A product, from circulation throughout the country. The authentic manufacturer of Dysport is Beaufour Ipsen Farmacêutica Ltda.
The seizure of the counterfeit Dysport (batch W13035) by Anvisa underscores significant risks for both healthcare professionals and patients. Counterfeit products can contain unsafe or ineffective ingredients, posing serious health risks, including allergic reactions, infection, or no therapeutic effect at all. Since counterfeit products are not manufactured under regulated conditions, their quality and purity cannot be guaranteed.
Healthcare professionals are advised to identify and isolate any products labeled as batch W13035, notify Anvisa about any suspected counterfeit products, follow any guidelines provided by Anvisa regarding the handling and disposal of counterfeit products, and inform patients who may have received the counterfeit product about the risks and provide guidance on any necessary follow-up care.
Patients should be aware of the risks associated with counterfeit medications and stay informed about any relevant updates. If a patient suspects they have received a counterfeit product or are experiencing adverse effects, they should seek medical attention immediately and report any suspicions regarding counterfeit products to Anvisa or their healthcare provider.
To ensure a safer healthcare environment, both healthcare professionals and patients should remain vigilant and check the authenticity of any medical products before use. They should also ensure that all medical products are obtained from authorized distributors to minimize the risk of receiving counterfeit items.
Anvisa has declared that the trade, distribution, and use of the counterfeit product are prohibited. The counterfeit product poses risks to public health, as previously stated by Anvisa. An alert about the risks the counterfeit product poses to public health was issued by Anvisa. It is of extreme importance to report suspected cases to local health surveillance authorities and police authorities. Doubt can be clarified directly with the manufacturer by calling 0800-7701820.
Botulinum toxin type A is used in both aesthetic and medical treatments. The counterfeit product affects healthcare professionals and patients who may have acquired or used the medication. By taking these steps, healthcare professionals and patients can mitigate the risks associated with counterfeit Dysport and ensure a safer healthcare environment in Brazil.
The seizure of the counterfeit Dysport (batch W13035) by Anvisa highlights the potential dangers of counterfeit medical-conditions products in the health-and-wellness sector. Science has shown that such products can lead to medical-conditions such as allergic reactions, infections, and even lack of therapeutic effects, which could be exacerbated by the unregulated production of counterfeit products.
